GLP-1s were originally created to help manage type 2 diabetes, but researchers have discovered they’re able to kill cravings for alcohol, cocaine, opioids, and nicotine. Most anti-addiction medications focus on one neurotransmitter, typically dopamine. GLP-1s don’t work that way. Instead, they target receptors located in the brain’s core reward circuit, the same areas that trigger cravings, relapses, and loss of control.
The reward circuit runs through three regions:
– the ventral tegmental area
– the nucleus accumbens
– the prefrontal cortex GLP-1 receptors have been mapped across this circuitry, confirmed directly in the PFC by a 30-brain human postmortem study, not animal models alone. Unlike other anti-addiction treatments, GLP-1s keep your baseline dopamine intact while specifically reducing the spikes caused by drugs. The effect shows up across almost every addictive substance researchers have tested:
GLP-1 Alcohol Use Disorder:
A Phase 2 randomized trial with semaglutide showed 13.7pp fewer heavy drinking days than placebo, ~500 fewer grams of alcohol per month, 1.5 fewer drinks per drinking day, and 10.1pp more alcohol-free days.
Opioids:
Early data indicated a 40% drop in cravings with liraglutide. In animal models, heroin, fentanyl, and oxycodone self-administration decreased after GLP-1R activation, without blocking the pain relief the opioid provided. The reward suppression was selective.
Nicotine:
A Phase 2a randomized trial published this year found once-weekly semaglutide reduced cigarette craving and body weight in daily smokers, even those not trying to quit. Earlier preclinical work also showed reduced self-administration and cue-triggered cravings.
The strongest evidence for GLP-1s yet comes from a 2026 study of over 600,000 US veterans. Starting a GLP-1 was linked to an 18% lower risk of alcohol use disorder, 20% lower risk for cocaine and nicotine, and 25% lower risk for opioid use disorder.
In people who already had a substance use disorder, starting a GLP-1 was linked to fewer overdoses, fewer hospitalizations, and lower mortality. Researchers called the consistency across substances unlike anything seen in addiction medicine before.
The strength of these effects varies significantly by patient. Researchers traced the gap to two separate factors: How well a person’s gut signal reaches the brain, and how deeply the drug itself penetrates the brain on its own. When researchers cut the vagus nerve in animal models, the anti-craving effects vanished completely. This means that individuals with low vagal tone, which is common in those with alcohol use disorder, might not benefit as much from GLP-1s for this reason.
Semaglutide can cross the blood-brain barrier more easily than other GLP-1s. In some patients, especially those using it for weight loss without any metabolic issues, it has been associated with increased depression, apathy, and in rare instances, suicidal thoughts. These psychiatric risks have not slowed development. If anything, they have pushed researchers toward designing more targeted compounds that aim to separate the reward-suppressing effects from the side effects that come with broader brain penetration. The next generation are dual and triple agonists, hitting GLP-1, GIP, and glucagon receptors. The idea is that combining these pathways enhances reward suppression while providing metabolic benefits. Whether this also increases psychiatric risks is still under investigation.
The next generation are dual and triple agonists, hitting GLP-1, GIP, and glucagon receptors. The idea is that combining these pathways enhances reward suppression while providing metabolic benefits. Whether this also increases psychiatric risks is still under investigation. Addiction medicine has been using blunt tools for years. GLP-1s are a different approach, acting as a gut hormone that influences the brain’s reward system from within. The mechanism is there, but the full picture isn’t clear yet.